Best Pharma Consulting Company

 What is Jardiance? how to use?

Jardiance (empagliflozin) is an inhibitor of sodium-glucose cotransporter 2 (SGLT2) and can be used as an aid to diet and exercise to improve blood sugar control in adults with type 2 diabetes. Jardiance can also reduce the risk of cardiovascular death in adults with type 2 diabetes and cardiovascular disease.

pharma consulting company

What are the side effects of cleverness?

Common side effects of Jardiance include:

  • Dehydration
  • dizziness,
  • Dizziness,
  • weakness,
  • Yeast infections,
  • Hypoglycemia,
  • nausea,
  • Upper respiratory tract infection,
  • High cholesterol,
  • Joint pain,
  • Increased urination,
  • Urinary Tract Infection
  • Thirsty, and
  • Low blood pressure (hypotension).

description

JARDIANCE tablets contain imaggliflozin, which is an orally active inhibitor of sodium-glucose cotransporter 2 (SGLT2).

pharma consulting company

The chemical name of empagliflozin is D-glucitol, 1,5-anhydro-1-C- [4-chloro-3-[[4-[[((3S)-tetrahydro-3furanyl]oxy) ]Phenyl]methyl]phenyl]-, (1S).

Its molecular formula is C23H27ClO7 and its molecular weight is 450.91. The structural formula is:

JARDIANCE® (empagliflozin) structural formula description

Empagliflozin is a white to light yellow non-hygroscopic powder. Slightly soluble in water, slightly soluble in methanol, slightly soluble in ethanol and acetonitrile. Soluble in 50% acetonitrile/water; almost insoluble in toluene.

Each JARDIANCE film-coated tablet contains 10 mg or 25 mg epagliflozin (free base) and the following inactive ingredients: lactose monohydrate, microcrystalline cellulose, hydroxypropyl cellulose, croscarmellose Base cellulose sodium, colloidal silica and magnesium stearate. In addition, the film coating also contains the following inactive ingredients: hypromellose, titanium dioxide, talc, polyethylene glycol and yellow iron trioxide.

Indications

JARDIANCE said:

As an aid to diet and exercise to improve blood sugar control in adults with type 2 diabetes,

Reduce the risk of cardiovascular death in adults with type 2 diabetes and diagnosed cardiovascular disease.

Use restrictions

It is not recommended to use JARDIANCE for type 1 diabetic patients or for the treatment of diabetic ketoacidosis.

Dosage and administration

Recommended dosage

The recommended dose of JARDIANCE is once a day, once a day, 10 mg each time, with or without food. In patients who tolerate JARDIANCE, the dose can be increased to 25 mg [see clinical studies].

For physically exhausted patients, it is recommended to correct this condition before starting JARDIANCE [see Warnings and Precautions, Use in Specific Populations and Patient Information].

Patients with renal insufficiency

It is recommended to assess renal function regularly before and after the start of JARDIANCE.

Patients with eGFR less than 45 mL/min / 1.73m² should not start JARDIANCE.

Patients with eGFR greater than or equal to 45 mL / min / 1.73m² do not need to adjust the dose.

If the eGFR continues to fall below 45 mL/min / 1.73m², then defensive measures should be discontinued (see "Warnings and Precautions and Use in Specific Populations").

Supply method

Formulations and advantages

The JARDIANCE tablet can be used as:

10 mg light yellow, round, biconvex and trimmed film-coated tablets with "S 10" embossed on one side and the Boehringer Ingelheim logo on the other side.

25 mg light yellow oval biconvex film-coated tablet with "S 25" engraved on one side and the Boehringer Ingelheim logo on the other side.

Storage and handling

The strengths of JARDIANCE tablets are 10 mg and 25 mg, as follows:

10 mg tablets: light yellow, round, biconvex and beveled edges, film-coated tablets, with "S 10" engraved on one side and the Boehringer Ingelheim logo on the other side.

30 bottles (NDC 0597-0152-30)

90 bottles (NDC 0597-0152-90)

The carton contains 3 blister cards, each with 10 pieces (3 x 10) (NDC 0597-0152-37), institutional packaging.

25 mg tablets: light yellow, oval, biconvex film-coated tablets with "S 25" recessed on one side and the Boehringer Ingelheim logo on the other side.

30 bottles (NDC 0597-0153-30)

90 bottles (NDC 0597-0153-90)

The carton contains 3 blister cards, each with 10 pieces (3 x 10) (NDC 0597-0153-37), in institutional packaging.

Dispensed in a closed container defined by USP.

Store

Store at 25°C (77°F); it is allowed to shift within the range of 15°-30°C (59°-86°F) [see USP controlled room temperature].

It is very challenging to find a good pharma consulting company which is rapidly growing with remarkable note, but there are some companies that provides numerous amount of pharmaceutical consulting services


Comments

Post a Comment

Popular posts from this blog

Best Pharma Consulting Company

Image
 Drug Name Atriance 5 mg/ml infusion solution 2. Qualitative and quantitative composition Each milliliter of solution contains 5 mg of Nelarabine. Each vial contains 250 mg of Nelarabine. Excipients with known effects Each milliliter of solution contains 1.770 mg (77 micromoles) of sodium. For a complete list of excipients, see section 6.1. 3. Drug form Infusion solution. Clear colorless solution. 4. Clinical details 4.1 Treatment indications Nelarabine is suitable for the treatment of patients with T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) who have not responded or relapsed after treatment with at least two chemotherapy regimens. Because the number of patients in these conditions is small, the information supporting these indications is based on limited data. 4.2 Modes and methods of administration Nelarabine can only be administered under the guidance of a doctor who has experience in the use of cytotoxic agents. Ontology The complete b...
Read more

Best Pharma Consulting Company

Image
  Indications Instruct VENCLEXTA: For the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Combine with azacitidine, decitabine or low-dose cytarabine for the treatment of newly diagnosed adult acute myeloid leukemia (AML): 75 years or older, or Patients with comorbidities cannot use intensive induction chemotherapy. Important safety information Contraindications In patients with CLL/SLL, simultaneous use of VENCLEXTA with strong CYP3A inhibitors is contraindicated because it may increase the risk of tumor lysis syndrome (TLS). Tumor lysis syndrome Patients treated with VENCLEXTA developed tumor lysis syndromes, including fatal events and renal failure requiring dialysis. VENCLEXTA can cause rapid tumor reduction, so in all CLL/SLL patients, there is a risk of TLS during the start and the start phase, and during the restart period after the dose is interrupted. Changes in blood chemistry consistent with TLS need to be dealt wi...
Read more

Best Pharma Consulting Company

Image
  About Veenat 400 mg tablets 10 Veenat 400 mg tablets belong to a class of drugs called "anti-cancer drugs" and are mainly used to treat various types of cancer. It is used to treat blood cancers (chronic myeloid leukemia and acute lymphocytic leukemia) and gastrointestinal stromal tumors. Cancer is a genetic change in which our cells divide uncontrollably and spread into surrounding tissues. There are more than 100 kinds of cancer, including blood cancer, lung cancer, breast cancer and so on. 10 Veenat 400 mg tablets contain imatinib, which is mainly used to treat cancer. It works by inhibiting the enzymes responsible for the proliferation of cancer cells and induces cell death (apoptosis). As a result, the growth and spread of cancer cells stopped or slowed down. Take 10 Veenat 400 mg tablets as prescribed by your doctor. It is recommended that you take 10 Veenat 400 mg tablets according to your doctor's condition, as long as your doctor has prescribed it for you. In s...
Read more